Johnson & Johnson (JNJ)
J&J begins crucial battle over $10 billion baby powder settlement
Johnson & Johnson faces a critical test on Tuesday over its $10 billion proposal to end litigation alleging that its baby powder caused ovarian cancer, as it tries to convince a judge to sign off on its third attempt to resolve thousands of lawsuits through a subsidiary's bankruptcy.
Johnson & Johnson: Rich History Of Excellence Poised To Endure
Johnson & Johnson offers a compelling balance of growth, innovation, and shareholder returns. JNJ's robust financials, including a fortress-like balance sheet and consistent dividends, support its ability to drive growth and innovation. The company is well-diversified across thriving healthcare segments, with promising FDA approvals and strategic M&A initiatives enhancing its market position.
J&J Stock Up More Than 6% in a Month: Time to Buy, Sell or Hold?
Those who own JNJ stock may stay invested for some time as the company looks optimistic about a better performance in 2025.
J&J resumes US rollout of Varipulse heart device after investigation
Johnson & Johnson said on Friday it has resumed the limited market release of its Varipulse heart device in the United States after an investigation found the devices operate as intended.
Johnson & Johnson halts late-stage E.coli vaccine trial after poor results
Johnson & Johnson and Sanofi said that while the vaccine showed no safety concerns, it did not meet the necessary effectiveness thresholds.
J&J to discontinue E.coli vaccine candidate study
Johnson & Johnson said on Thursday it will discontinue a late-stage study of an experimental E.coli vaccine it was developing in partnership with Sanofi.
What's a Fair Price to Buy Johnson & Johnson Stock?
Johnson & Johnson (JNJ 1.23%) is forecast to increase its free cash flow significantly over the next five years and beyond.
Are You Looking for a High-Growth Dividend Stock?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
DCLA's Sarat Sethi on his top stock picks: JNJ, WDAY, TMO
Sarat Sethi, DCLA managing partner, joins 'Squawk Box' to discuss the latest market trends, his top stock picks, and more.
You Deserve Reliable Income: 2 Undervalued Dividends For Long-Term Growth
A buy-and-hold strategy is ideal for investors seeking durable companies with strong dividends and attractive valuations, avoiding tax inefficiencies from frequent trading. UPS offers a 5.7% dividend yield, trading at a forward P/E of 13.5, with potential for profitability expansion despite near-term Amazon volume reductions. Johnson & Johnson, with a 3.3% dividend yield and a forward P/E of 14.4, carries a robust pipeline and 62 years of consecutive dividend growth.
Is Johnson & Johnson Stock a Buy?
Johnson & Johnson (JNJ -0.47%) is one of the world's largest and most prominent healthcare leaders. If investing in a company came down to size, the stock would be a no-brainer buy.
